Vancomycin intermittent dosing versus continuous infusion for treatment of ventilatorassociated pneumonia in trauma patients

American Surgeon

Volumn 79, Issue 11, 2013, Pages 1185-1190

  Schmelzer, Thomas M ^a   Christmas, A Britton ^a   Norton, H James ^a   Heniford, B Todd ^a   Sing, Ronald F ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IODINATED CONTRAST MEDIUM; NONSTEROID ANTIINFLAMMATORY AGENT; VANCOMYCIN;

ADULT; AGE; BODY WEIGHT; COMORBIDITY; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJURY SCALE; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84886678036     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171: 388-416.
2. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29: 1171-7.
3. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124: 1789-97.
4. Fagon J, Patrick H, Haas DW, et al. Treatment of Grampositive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161: 753-62.
5. Malangoni MA, Crafton R, Mocek FC. Pneumonia in the surgical intensive care unit: factors determining successful outcome. Am J Surg 1994;167: 250-5.
6. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006;12: 92-5.
7. Garnacho-Montero J, Garcia-Garmendia JL, Barrero- Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31: 2742-51.
8. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38: 865-9.
9. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance - what's dosing got to do with it? Crit Care Med 2008; 36: 2433-40.
10. Pea F, Viale P. Should the currently recommended twicedaily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008;47: 147-52.
11. Boffi El Amari E, Vuagnat A, Stern R, et al. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis 2004;36: 712-7.
12. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166: 2138-44.
13. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob Agents Chemother 1996;40: 696-700.
14. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45: 2460-7.
15. Rello J, Sole-Violan J, Sa-BorgesM, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005;33: 1983-7.
16. Klepser ME, Patel KB, Nicolau DP, et al. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy 1998; 18: 1069-74.
17. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005;44: 1009-34.